Table 5. Summary of pharmacokinetic parameters.
| BMS-936558Dose (mg/kg) | N | Cmax (µg/mL)g. mean (% CV) | Tmax (hours) median (min-max) | AUC0-T (µg·h/mL)g. mean (% CV) | AUCINF (µg·h/mL)g. mean (% CV) | T½ (days) mean (SD) |
| 0.03a | 3 | 1.41 (17) | 3.25 (1.8–6.3) | 4.20 (151) | NR | NR |
| 0.1 | 5 | 3.52 (129) | 0.63 (0.5–3.0) | 113 (99) | NR | NR |
| 0.3 | 5 | 6.86 (21) | 1.03 (1.0–3.0) | 1597 (35) | NR | NR |
| 1 | 5 | 26.8 (13) | 1.27 (1.0–4.0) | 7377 (17) | 8537 (19) | 20.6 (2.81) |
| 3 | 5 | 80.4 (14) | 1.50 (1.3–3.0) | 26,189 (17) | 28,799 (19) | 23.2 (4.69) |
| 10 | 20 | 195 (20) | 1.75 (1.0–48.0) | 74,378 (17) | 81,022 (20) | 23.7 (4.41) |
a
Two subjects in the 0.03 mg/kg dose cohort had serum drug concentrations below the assay lower limit of quantitation for all time points and were excluded from pharmacokinetic statistical analyses.
NR = Not reported; the AUCINF extrapolated area was >20% of the total area resulting in undue potential for error.